The respiratory syncytial virus has raised a state of concern during the past few days in Egypt with its large spread amongst children. In the meantime the global drug manufacturer Pfizer has announced a new vaccine that protects infants and the elderly from the risk of respiratory syncytial virus infection. Respiratory syncytial virus vaccine:With the spread of respiratory syncytial virus (RSV) infections in the US, Pfizer announced the production of a vaccine to fight against the virus that spreads amongst mostly children. The Pfizer vaccine is expected to be released, after obtaining the approval of the US Food and Drug Administration by the end of 2022. If approved, Pfizer’s RSV vaccine will be the first maternal vaccine available to help prevent this common and potentially life-threatening respiratory disease in young infants.

Source: Egypt Independent November 18, 2022 10:29 UTC